Services

Browse our partial list of Services to Advance your Market Access Success

Market Access & Value

Reenvisioning market access engagements

Reimagining pharma/biotech market access engagements involves strategic partnerships with payers and integrated providers, moving beyond traditional and mostly transactional market access approaches toward a collaborative focus on delivering comprehensive patient care.

Prioritizing collaboration, pharma/biotech firms engage proactively, co-creating solutions aligned with evolving healthcare needs. Initiatives include real-world evidence generation, joint educational programs, and value-based contracts linking reimbursement to outcomes. Embracing a holistic patient-centric model, companies contribute to better health outcomes. Leveraging data analytics and technology enhances communication efficiency, fostering an agile response to healthcare changes.

This reenvisioned approach positions pharma/biotech companies as vital partners in patient-centered care, benefiting all stakeholders.

Pharmaceutical Life Cycle graph

Original image source from ValuationLAB

Perigee's Market Access services are structured around four pillars, emphasizing the growing strategic significance of market access to a Brand’s success.

  1. Value Story & Access

  2. Coverage & Reimbursement

  3. Brand Team Coordination & Alignment

  4. Creativity & Innovation

Our goal is to ensure the maximum number of suitable patients have timely access to our client’s brand for the optimal reimbursed price throughout its lifecycle.

Prelaunch – focus on Launch Planning

  • Access strategy development – reimbursement, formulary placement strategies, and access support services

    Unbranded messages and Disease Education assets

    Customer Segmentation & Targeting

    Inflation Reduction Act & other Policy Assessments

    Multi-channel Communications Strategy

    Market Research & Message Testing (qualitative and quantitative)

    Stakeholder Mapping and Engagement

    Long-term Value demonstration - post-launch studies, lifecycle management strategies, and ongoing engagement with stakeholders to continually demonstrate and enhance the product's value proposition

  • Competitive Intelligence & benchmarking strategy - Landscape assessments including competitor activities, market dynamics & benchmarking against industry standards

    Literature landscape review to identify Data Gaps

    Pricing Research (Qual and Quant)

    Burden of illness Assessment and Disease Awareness

    Health economics and outcomes research

    Market Research - 1 on 1 in depth interviews (IDIs

    Regulatory landscape analysis– regulatory pathways, potential hurdles & engaging with regulatory agencies to understand label which may drive PA&UM processes.

  • Real World Evidence (RWE) - demonstrating a product's value proposition in real-world clinical practice settings

    Advisory Boards (payer and IDN stakeholders)

    Mock Formulary Committee Meetinga

    Disease Dashboards™ - disease-specific and patient-centric data-informed patient journey/roadmap³

    Government payer- and Employer-driven assets

    White Paper publication and Clinical Reprints

    Payer Value Propositions/Message Development

  • Preapproval Information Exchange (PIE) presentations

    Global considerations - depends on intended market reach and involves understanding differences in regulatory requirements, healthcare systems, and payer landscapes across different regions.

Launch and Growth – focus on Value Creation

  • Launch Announcement Emails

    Product Fact Sheets

    Prior Authorization and Insurance Appeal templates

    Coding and Billing Guides

    Patient Support Programs

    Association/Congress/Conference Support

    Formulary Flashcards and Coverage Update Leave-Behinds

    Digital and Print Ads

    Access and reimbursement support for office staff

  • Budget Impact Models

    Cost-effectiveness models

    Economic evaluations

    Patient Support and Reimbursement Experience Mapping

    Clinical and Cost/Value Visual Aids

    Population health and SDoH communications

  • Data Analytics and Data-Informed Resources

    Disease Dashboards™

    Publication Planning

  • Value communication tools (E-Formulary Brochures/Kits, AMCP Dossiers, Clinical cost/value visual aids)

    Publicity and engagement efforts (Association/Congress/Conference Support)

    Population health and SDoH communications

    Patient Support Programs

Maturity/Expiry – shift to Value Preservation

  • Lifecycle management strategies

    Strategic Contracting

    Reassessment of Core Value Messages and Tools

    Disease Dashboards™

    RWE translation assets

  • Patient Access programs

    Proactive management of reimbursement challenges

    Pull-through and Field Integration

    Reimbursement Initiatives and Support

  • Ongoing Qualitative Research and Market Assessments

    Qualitative Research, Market Assessments and engagement with key stakeholders

  • HEOR/Economic Models

    Cost Effectiveness Models/Calculators

Our connections

Our robust capabilities in market access, value and reimbursement are enhanced by powerful industry alliances. Collaborating with prominent healthcare organizations and thought leaders, we ensure that our clients benefit from the most relevant, up-to-date, and comprehensive expertise in our work.

Network of Key Opinion Leaders

Actuarial Evidence Firms

Pricing & Contracting

Data Analytics Experts  

Patient Financial Assistance Programs

[3] Strategic use of FDAMA, Section 114: Our work with Disease Dashboards™ and other data-informed resources leverage the Food and Drug Administration Modernization Act of 1997 (FDAMA) and Section 3037 of the 21st Century Cures Act to effectively demonstrate cost impact in a compliant manner.